Summer Street Starts Ligand Pharma (LGND) at Buy, Sets $22 Price Target

Article Stock Quotes (1) Comments (0)

Shares of Ligand Pharma (NASDAQ: LGND) are pushing lower Friday morning despite a new Buy rating from an analyst at Summer Street. The firm set a $22 price target on the stock.

With shares down 1 percent to $11.84 at last check, Summer Street's new price target implies potential upside of about 86 percent.

For an analyst ratings summary and ratings history on Ligand Pharma click here. For more ratings news on Ligand Pharma click here.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Ligand to Present at Upcoming Investor Conferences
• Topeka Capital Starts InvenSense (INVN) at Buy
• Ligand Pharmaceuticals (LGND) Agreement with Merck KGaA Unit Terminated

Create E-mail Alert Related Categories

New Coverage

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?